Colinz Laboratories Limited (BOM:531210)

Market Cap	128.30M +0.6%
Revenue (ttm)	61.36M -6.0%
Net Income	5.15M +3.6%
EPS	2.04 +3.6%
Shares Out	2.52M
PE Ratio	24.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,430
Open	45.28
Previous Close	46.20
Day's Range	45.28 - 48.51
52-Week Range	36.11 - 87.91
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 29, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin,...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Employees: 65
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531210

Financial Performance

In fiscal year 2026, Colinz Laboratories's revenue was 61.36 million, a decrease of -6.00% compared to the previous year's 65.28 million. Earnings were 5.15 million, an increase of 3.60%.